Nicholas Yoder

Company: Dyne Therapeutics

Job title: Executive Director, Platform Development

Seminars:

The FORCE™ Platform for Transferrin Receptor 1-Mediated Delivery of Oligonucleotides to Muscle and CNS 8:30 am

Dyne’s FORCE Platform was designed to deliver oligonucleotides to muscle cells via conjugation to a transferrin receptor 1 (TfR1)-targeting Fab, and is currently in clinical development for the treatment of myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). Consistent with TfR1-mediated uptake, we observe robust delivery of conjugated ASO to the brain of…Read more

day: Conference Day One